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Abstract
Background: The ends of chromosomes, termed telomeres consist of repetitive DNA. The telomeric sequences 
shorten with cell division and, when telomeres are critically abbreviated, cells stop proliferating. However, in cancer 
cells, by the expression of telomerase which elongates telomeres, the cells can continue proliferating. Many 
approaches for telomere shortening have been pursued in the past, but to our knowledge, cutting telomeres in vivo 
has not so far been demonstrated. In addition, there is lack of information on the cellular effects of telomere shortening 
in human cells.
Results: Here, we created novel chimeric endonucleases to cut telomeres by fusing the endonuclease domain 
(TRAS1EN) of the silkworm's telomere specific non-long terminal repeat retrotransposon TRAS1 to the human 
telomere-binding protein, TRF1. An in vitro assay demonstrated that the TRAS1EN-TRF1 chimeric endonucleases (T-EN 
and EN-T) cut the human (TTAGGG)n repeats specifically. The concentration of TRAS1EN-TRF1 chimeric endonucleases 
necessary for the cleavage of (TTAGGG)n repeats was about 40-fold lower than that of TRAS1EN alone. When TRAS1EN-
TRF1 endonucleases were introduced into human U2OS cancer cells using adenovirus vectors, the enzymes localized 
at telomeres of nuclei, cleaved and shortened the telomeric DNA by double-strand breaks. When human U2OS and 
HFL-1 fibroblast cells were infected with EN-T recombinant adenovirus, their cellular proliferation was suppressed for 
about 2 weeks after infection. In contrast, the TRAS1EN mutant (H258A) chimeric endonuclease fused with TRF1 
(ENmut-T) did not show the suppression effect. The EN-T recombinant adenovirus induced telomere shortening in 
U2OS cells, activated the p53-dependent pathway and caused the senescence associated cellular responses, while the 
ENmut-T construct did not show such effects.
Conclusions: A novel TRAS1EN-TRF1 chimeric endonuclease (EN-T) cuts the human telomeric repeats (TTAGGG)n 
specifically in vitro and in vivo. Thus, the chimeric endonuclease which is expressed from an adenoviral vector can 
suppress cell proliferation of cancer cells.
Background
Telomeres are specialized structures that protect chro-
mosomal ends from gene erosion at cell divisions, nonho-
mologous chromosomal end joining and nuclease attack
[1]. The DNA component of telomeres, typically 5-8 kb
long, consists of tandem arrays of short, repetitive G-rich
sequences--TTAGGG in vertebrates--oriented 5'- to -3'
towards the end of the chromosome [2]. Each replication
of human nuclear DNA results in a 50-200 base pair loss
of the telomere. After reaching a critical shortening of the
telomere, the cell enters replicative senescence or under-
goes programmed cell death [3]. In striking contrast, the
length of telomeres in cancer cells does not shorten dur-
ing replication and remains constant over succeeding
generations. This is because of the characteristic enzyme,
telomerase, which is expressed in more than 80% of
human cancers [4]. Expression of telomerase is not
induced in normal human tissues and somatic cells and is
usually limited to germline cells. Hence, telomerase is
potentially a molecular target for developing antitumour
agents [5]. However, as mentioned above, because telom-
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Page 2 of 16eres shorten by 50-200 bases every cell division under
physiological conditions, it takes a long time with con-
ventional telomerase inhibitors (~1 month) [6] to induce
effective telomere shortening followed by cellular senes-
cence. In order to induce this rapidly, we investigated a
novel method of shortening telomeres with the endonu-
clease domain of a telomere-specific non-long terminal
repeat (LTR) retrotransposon, TRAS1.
Non-LTR retrotransposons, also known as long inter-
spersed nuclear elements (LINEs), are transposable ele-
ments that insert into the genome via RNA
intermediates. Most such transposable elements integrate
into the genome randomly, although some LINEs have
very restricted target sequences for integration [7].
TRAS1, found in the silkworm Bombyx mori, is a typical
sequence-specific LINE, which inserts between the T and
A of the (TTAGG)n telomeric repeats of the silkworm [8].
The second open reading frame (ORF2) of TRAS1
encodes an apurine/apyrimidine (AP) endonuclease-like
domain (EN) at the N-terminal end [9]. The EN domain
of TRAS1 (TRAS1EN) cuts the specific target sites of
(TTAGG)n/(CCTAA)n telomeric repeats during target-
primed reverse transcription, which is an essential pro-
cess for LINEs [10]. TRAS1EN also cleaves the vertebrate
telomeric repeats, (TTAGGG)n and several other telom-
ere sequences in different species [11]. Thus, if TRAS1EN
could cut telomeres in human cancer cells specifically
and effectively, we hypothesized that the proliferation of
cancer cells would be inhibited.
We have determined the crystal structure of TRAS1EN
[11], which is basically similar to the AP endonuclease
family, but has a special beta-hairpin at the DNA binding
surface. Mutational studies of TRAS1EN indicated that
the Asp-130 and β10-β11 hairpin structures are involved
in specific recognition of telomeric repeats. We also anal-
ysed the structure of the EN of the silkworm 28S rDNA-
specific LINE R1 (R1BmEN) and found that a Y98A
mutant of R1BmEN on the DNA binding surface had
altered cleavage patterns [12,13]. These results suggest an
important role of the DNA binding surface in the EN of
LINE for target sequence recognition and for the de novo
design of a novel sequence-specific EN with altered
sequence specificity for human telomeric repeats.
Although in silico screening has been done for the hom-
ing endonuclease I-MsoI [14] to redesign its DNA bind-
ing and cleavage, it is still difficult to redesign in silico for
changing the specificity of EN of LINE [15].
TRAS1EN cleaves human (TTAGGG)n telomeric
repeats but its activity level and specificity seemed to be
insufficient for practical application. In order to increase
its ability, we used the human telomere-binding protein
TRF1. The shelterin complex, consisting of six telomere-
specific proteins including TRF1, protects the chromo-
somal ends. TRF1 has a Myb domain at its C-terminal
end, which recognizes the double-strand DNA sequence
TTAGGGTTA [16] and controls telomere length nega-
tively [17]. We created chimeric endonucleases of
TRAS1EN with either a full length of TRF1 or only the
Myb domain of TRF1 and examined their abilities to cut
vertebrate telomeric repeats. Here, we show that these
TRAS1EN-TRF1 chimeric endonucleases cut TTAGGG
repeats specifically in vitro and in vivo. They induce telo-
meric shortening and suppress cell proliferation when
introduced into cancer cells.
Results
Construction and expression of chimeric endonucleases
In order to increase the cleavage activity for human telo-
meric TTAGGG sequences, we constructed several types
of chimeric endonuclease versions of TRAS1EN (EN),
which cuts the silkworm TTAGG repeats by fusing wild-
type TRAS1EN with various parts of TRF1 (T) either at
the N- or C-terminal ends of TRAS1EN (Figure 1a). TRF1
has three domains: the homodimerization region
(TRFH), a nuclear localization signal (NLS) and a telo-
meric DNA binding motif (Myb). Thus, we made chime-
ric EN constructs with a full-length sequence of TRF1 (T-
EN, EN-T): only the TRF1-Myb component (M-EN, EN-
M) and with the NLS to Myb region of TRF1 (EN-NM).
As a negative control, we constructed a TRAS1EN
mutant (ENmut, H258A) which has a mutation in the cat-
alytic center that inactivates the endonuclease activity [9],
and made respective chimeric constructs with TRF1 (T-
ENmut, ENmut-T). We also used the nonspecific cleav-
age domain of a restriction enzyme FokI (FN) which is
often used for chimeric endonuclease design [18] and
made FN constructs with a full length of TRF1 (T-FN,
FN-T) (Figure 1a). We performed three-dimensional pro-
tein modelling in order to estimate each linker length of
the chimeric constructs, based on the crystal protein
structures. Figure 1b shows an example of the linker
design (yellow line) in TRF1-Myb (M; green) and
TRAS1EN (EN; cyan) of the chimeric endonuclease M-
EN. The predicted structure of M-EN showed that the
distance between M and EN was around 2-4 nm, indicat-
ing that the length of flexible linker between M and EN
should be longer than 10 amino acids (assuming a peptide
unit length of 3.8 Å), so that the EN domain can access
target DNA effectively [19]. Similarly, we estimated and
designed the linker for each chimera construct (Addi-
tional file 1). We expressed chimeric proteins with
Rosetta2 Escherichia coli strain overexpressing tRNAs for
rare codons and chaperons to enhance protein expression
(Additional file 2a), analysed their qualities and quantities
(Additional file 2b) and purified the proteins using the
His tag.
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Figure 1 Construction and structure of chimeric endonucleases. (a) A schematic representation of fusion proteins constructed into pET21b for 
expression in Escherichia. coli is shown with the restriction sites. EN, TRAS1 endonuclease domain; FN, restriction endonuclease FokI cleavage domain; 
TRF1, human telomere binding protein; TRFH, TRF heterodimerization region; NLS, nuclear localization signal; Myb, telomeric DNA binding motif. Es-
timated molecular weight and linker length are shown. (b) A model of the chimeric protein M-EN is shown with the N-terminal TRF1 Myb domain in 
green, the C-terminal TRAS1EN in cyan, and the interdomain hypothetical linker in yellow.
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effectively
In order to assess the cleavage property of each chimeric
endonuclease in vitro, the purified protein was added to a
reaction mixture including the linearized plasmid DNA
containing human (TTAGGG)80 telomeric repeats
(pTR80) or nontelomeric sequence (pNTR; see Methods).
When a chimeric endonuclease has the ability to cleave
human telomeric repeats, pTR80 (3.5 kbp), which has
(TTAGGG)80 repeats in the centre, is expected to be
digested into approximately 1.8 kb and 1.2 kb fragments
(Figure 2a). We found that our chimeric endonucleases
(T-EN, M-EN, EN-T, EN-NM, EN-M, T-FN and FN-T)
cut the pTR80 plasmid and produced additional 1.8 kb
and 1.2 kb bands (Figure 2b, lanes 4-8, 13 and 14, respec-
tively), although the nonfused proteins (T, M and EN;
lanes 2, 3 and 9, respectively), a mutant TRAS1EN pro-
tein (ENmut; lane 12) and its chimeric proteins with
TRF1 (T-ENmut, ENmut-T; lanes 10, 11) did not show
the additional bands for pTR80. Although it has been
reported that TRAS1EN cleaves vertebrate telomeric
repeats [11], TRAS1EN itself (EN, lane 9) did not cleave
pTR80 effectively in this study because of a low concen-
tration of purified TRAS1EN. None of the fused and non-
fused proteins showed any extra bands for the
nontelomeric plasmid pNTR (Figure 2b, lanes 16-30).
Thus, these chimeric EN endonucleases and chimeric FN
endonucleases fused with the human telomere binding
protein TRF1 or with its Myb domain, specifically and
effectively cleaved the human (TTAGGG)n telomeric
repeats. As far as we know, this is the first report of endo-
nucleases which cleave (TTAGGG)n more effectively than
other sequences.
Activity and specificity of the chimeric endonucleases
We further evaluated the cleavage activity of each chime-
ric endonuclease as described below. Linearized pTR80
or pNTR was added to a dilution series of protein and
incubated at 25°C for 30 min. Then the ratio of cleaved
bands to uncleaved linear plasmid was calculated using
agarose gel electrophoresis (Figure 3a-i). The EC50,
defined as the concentration of protein that cuts half of
the plasmid, for pTR80 of nonfused TRAS1EN (EN) was
3.9 μM (Figure 3a). In contrast, the EC50s for pTR80 of
chimeric EN endonucleases (Figure 3c, M-EN; Figure 3d,
T-EN; Figure 3e, EN-M; Figure 3f, EN-NM; Figure 3g,
EN-T) were much lower (0.09-0.19 μM) (Figure 3, Addi-
tional file 3), suggesting that purified TRAS1EN has only
2%-5% of the specific cleavage activity of the purified chi-
meric endonucleases. In order to compare the cleavage
activity of each chimeric endonuclease, the relative activi-
ties for pTR80 and pNTR were calculated from recipro-
cals of each EC50 (Additional file 3). The relative
activities of five chimeric EN endonucleases (M-EN, T-
EN, EN-NM, EN-M and EN-T) for pTR80 were 21-45-
fold higher than that of TRAS1EN alone (Figure 3j, Addi-
tional file 3). The EC50s for pNTR of EN-T, T-FN and
FN-T could not be determined, because the purified pro-
tein concentration was too low to induce nonspecific
cleavage. FN-T showed the highest in vitro cleavage activ-
ity for pTR80 because it was 364 times higher than that of
TRAS1EN and it cleaved 20 times more telomeric repeats
than nontelomeric sequences. EC50s for pTR80 and
pNTR of TRAS1EN were the same (Figure 3a). This may
appear to be conflicting with our previous report of
TRAS1EN being the telomere cleavage endonuclease
[11]. This could be explained by the different substrates
used in the two studies. While in this study we used the
pTR80 plasmid with telomeric repeats accounting for
14% of the substrate DNA, in the previous report
(TTAGGG)n-oligonucleotides served as substrates
requiring a lower enzymatic specificity [11]. Moreover,
pTR80 contains human telomeric repeats, whereas the
cleavage activity of TRAS1EN is maximum when silk-
worm telomeric repeat (TTAGG)n is the target sequence.
Binding and cleavage of telomeric repeats by chimeric 
endonucleases
In order to understand how our chimeric endonucleases
cut the telomeric repeats, we analysed cleavage sites in
end-labelled oligo DNA TR5 containing (TTAGGG)5
repeats, digested with chimeric endonucleases (Addi-
tional file 4). We found that chimeric TRAS1EN endonu-
cleases cleaved the T-A junction of the TTAGGG strand
and the C-T junction of the CCCTAA strand, which is
consistent with the cleavage sites for TRAS1EN [11]. This
demonstrates that the specificity of these chimeric endo-
nucleases was not changed even though TRAS1EN was
fused with TRF1 domains. Interestingly, the cleavage sites
of the two chimeric FN endonucleases (cleavage site
(C|CCTAA) in T-FN and (CCCTA|A) in FN-T) on the
CCCTAA strand were different from each other. The
linker lengths of T-FN and FN-T are quite different,
which might affect their respective cleavage sites on the
CCCTAA strand [20].
Next, we performed electrophoretic mobility shift
assays (EMSAs) to test the binding capacities of chimeric
endonucleases to the telomeric repeats. Like TRF1 (T)
and its Myb domain (M) [16], all EN and FN chimeric
endonucleases bound to the telomeric oligonucleotide
TR5 (Additional file 5a), but not to the nontelomeric
sequence (NTR) (Additional file 5b), suggesting that chi-
meric endonucleases recognize telomeric repeats based
on the binding specificity of TRF1.
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In order to test whether these endonucleases also cleave
the telomeric repeats in vivo, we introduced endonu-
clease constructs into two telomerase-negative cancer
cell lines, U2OS and CCF-STTG1, and a normal fibro-
blast cell line HFL-1 using adenovirus vector. Genomic
DNA was collected 3 days after virus infection and the
telomere length was measured by Southern hybridization
(see Methods). In the case of U2OS, CCF-STTG1 and
HFL-1 cells, which have long telomeric repeats (over 10
kb), the band intensity of telomeric repeats decreased
drastically when EN-T adenovirus was infected, but did
not change when GFP-TRF1 (G-T) and FN-T viruses
were infected, in comparison with no virus infection (Fig-
ure 4a-d). The human L1 sequence and centromeric
alpha satellite were used as a nontelomeric internal con-
trol for equal loading, and for the comparison of non-spe-
cific cleavage, and its banding patterns were not changed
in any treatment (Figure 4a-d). These data demonstrate
Figure 2 In vitro cleavage of human telomeric repeats by chimeric endonucleases. (a) Schematic representation of cleavage assay. pTR80, 80 
TTAGGG repeats were inserted in the TA cloning site of pGEM-T Easy vector. pNTR, a non-telomeric sequence inserted in the same vector (see Meth-
ods). (b) Digestion patterns with various chimeric endonucleases. Plasmids (36 ng) were added with about 0.3 μM purified proteins, except for FN-T 
(about 0.02 μM), and incubated for 2 h at 25°C and separated by agarose gel electrophoresis. Lanes 1 ~ 15: pTR80/ScaI, lanes 16 ~ 30: pNTR/ScaI.
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Figure 3 Comparison of cleavage activity of chimeric endonucleases. (a-i) pTR80/ScaI or pNTR/ScaI was mixed with purified protein. Cleaved 
plasmid was separated by electrophoresis and the intensity of bands corresponding to uncleaved plasmid was determined using a densitometer and 
ImageJ (bar: ± standard deviation). The cleavage for pTR80 and pNTR is shown by solid line (with filled circles) and dotted line (with open triangles), 
respectively, in each figure. Protein concentration (μM) is shown on the horizontal axis. EC50 is shown as black arrow head for pTR80 and gray arrow 
head for pNTR. (j) The reciprocal EC50s of chimeric endonucleases for pTR80/ScaI and pNTR/ScaI were calculated (bar: ± 95% confidence interval), and 
each relative activity is shown based on the value of reciprocal EC50 of EN for pTR80/ScaI as 1.
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Figure 4 In vivo cleavage of human telomere by chimeric endonucleases. We expressed chimeric endonucleases (G-T, EN-T, FN-T) mediated by 
adenovirus (MOI: 100) and collected genomic DNA 3 days after infection (see Methods). G-T, GFP-TRF1; -, no virus infection. Using telomeric repeats 
as a probe, we performed Southern hybridization for terminal restriction fragment (TRF) assay in order to analyse telomere length. We used L1 probe 
(the sequence is shown in Additional file 6) (a, c and d), and alpha satellite probe (b) as an internal control. (e) Telomere digestion by chimeric endo-
nucleases in U2OS cells. We added each virus construct at MOI 100, 10, 1 (left to right lanes) to the cells, and performed a TRF assay with the same 
procedure as in (a). G, GFP; other abbreviations (see Figure 1a or text). (f) Protein expression in U2OS cells after adenoviral infections. Expressed proteins 
used in (e) were confirmed by western blotting using anti-HA antibody. The amounts of expressed proteins are directly proportional to viral titers.
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and effectively not only in vitro but also in human cell
lines in vivo. Unexpectedly, FN-T, which showed the
highest activity in vitro (Figure 3j), did not cut the telo-
meric repeats in human cells. Using U2OS cells showing
the most evident telomere digestion in Figure 4a-d, we
tested the telomere cleavage by various adenovirus con-
structs with MOI 100, 10 and 1 (Figure 4e). Two con-
structs, T-EN and EN-T cleaved telomeric repeats clearly
but other constructs, including the TRAS1EN mutant
fusion proteins (T-ENmut and ENmut-T), did not alter
band intensity. We confirmed that each protein was nor-
mally expressed and increased proportionally to the virus
titre (Figure 4f).
Subcellular localization of telomere specific chimeric 
endonucleases
As the TRF1 protein is known to accumulate around
telomeres [21], we analysed in order to see if our chimeric
endonucleases also localize at telomeres. The subcellular
localizations of chimeric endonucleases expressed with
HA tags were detected with an anti-HA antibody and
telomeres were detected with an antibody against TRF2,
another component of the shelterin complex [16]. We
found that all chimeric endonucleases, except for T-FN,
localized at telomeres, as shown by yellow signals in the
merged image seen in Figure 5a. The T-FN chimeric
endonuclease seemed not to migrate into the nucleus
(Figure 5a), which may explain why T-FN could not cut
telomeric repeats in cells (Figure 4e).
Indirect immunofluorescence of γH2AX, which is a
double-strand-break marker [22], visualized telomere
cleavage by chimeric endonucleases in U2OS cells (Figure
5b). Only after infection with the T-EN or EN-T adenovi-
rus did we observe many co-localized spots of chimeric
endonuclease and γH2AX (yellow signals in the merged
and enlarged images). There were some background
γH2AX signals in PML bodies [22,23] without virus
infection. Using NIH Image J software, we quantified
colocalization of HA and γH2AX signals (Figure 5c) and
found that 34% of T-EN and 27% of EN-T foci localized at
double-strand breaks. These observations confirmed that
both T-EN and EN-T localize at telomeres and cut telo-
meric DNA.
Inhibition of cell proliferation
We examined whether the telomere shortening induced
by chimeric EN endonucleases could repress the cell pro-
liferation directly. A low concentration of recombinant
adenoviruses was added to U2OS and HFL-1 human cells
at each passage, every 3-4 days. Twenty-five days after
viral infection, the growth of U2OS tumour cells infected
with EN-T-expressing adenovirus was inhibited at the
higher dose (Figure 6b). In contrast, U2OS cells infected
with adenoviruses expressing chimeric proteins, G-T, FN-
T, ENmut-T and EN showed normal growth similar to the
cells expressing only GFP (G). We further analysed HFL-1
fibroblasts, which have no telomerase activity to elongate
shortened telomere. The growth of HFL-1 cells infected
with EN-T virus was more clearly inhibited than that of
U2OS with the same virus (Figure 6c, d). HFL-1 cell cul-
tures infected with EN-T adenovirus titres of 8.8 pfu/ml
were dead by day 17 after infection.
Then we explored the senescence status of U2OS
tumour cells expressing chimeric EN endonuclease. Con-
sistent with the results presented in Figure 6b, EN-T
expression suppressed proliferation of U2OS cells 2
weeks after infection, while ENmut-T did not exhibit
such suppression effect (Figure 7a). We measured telom-
ere length at day 3, 7 and 13 after infection to analyse
telomere digestion by EN-T and other expression prod-
ucts (Figure 7b). Telomere digestion was detected from
day 7 with the EN-T virus, while not with other viruses
including ENmut-T. We also compared the gene expres-
sion levels of p53 and p16INK4a (p16) after viral infection
(Figure 7c). The p53 and p16 proteins are known as key
factors in the telomere DNA damage response. In the
experiment of telomere loop structure disruption by
overexpression of dominant negative TRF2 (TRF2ΔBΔM),
p53 was induced within a few days and p16 was induced
after 8-10 days [24]. The p53 and p16 proteins induced
cellular senescence independently by inhibiting their
downstream target cyclin-dependent kinase [25]. In this
experiment, the expression of p53 was induced with EN-
T virus 7 days after viral infection, but the level of p16
remained stable (Figure 7c). ENmut-T expression also
activated p53 slightly, this could be because TRF1-over-
expression affected cell cycle progression [26]. Neverthe-
less, EN-T expression clearly has the strongest effect on
p53 activation. It was confirmed that the amount of EN-T
protein was almost equal to that of ENmut-T (Figure 7c,
HA). We also performed a senescence-associated (SA) β-
galactosidase assay in order to detect cellular senescence.
EN-T-expressing cells showed senescent phenotype, an
enlarged and flattened appearance and increased SA β-
galactosidase activity (Figure 7d). We found that 70% of
cells infected with EN-T virus were positive for SA β-
galactosidase staining, while only 14% with the ENmut-T
virus (Figure 7e). These results indicate that EN-T virus
induces cellular senescence through telomere shortening
and represses cell proliferation.
Discussion
Type IIS restriction endonucleases (REases) such as FokI
and BmrI, which have a specific DNA binding domain
and a nonspecific DNA cleavage domain separately, are
useful to create new sequence-specific endonucleases
[18,27]. For this purpose, DNA binding domains such as
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Figure 5 Subcellular localization of expressed chimeric endonucleases. (a) Telomere localization of expressed chimeric endonucleases. We in-
fected adenovirus that expresses a chimeric endonuclease at MOI 100 to U2OS cells and performed indirect immunofluorescence the next day. Fusion 
proteins were detected with anti-HA antibody (green), and telomere was detected with anti-TRF2 antibody (red). Nuclei were stained with 
Hoechst33342. Yellow dot signals represent the colocalization of fusion protein and telomere. The scale bar is 10 μm. (b) Telomere cleavage by ex-
pressed chimeric endonucleases. In order to visualize telomere cleavage by chimeric endonucleases, fusion proteins were detected with anti-HA an-
tibody (green) and DNA double-strand breaks were detected with anti-γ-H2AX antibody (red). (c) Based on the results in (b), we calculated the ratio 
(%) of co-localized spots (yellow) to fusion protein signals (green) using ImageJ (bar: 95% confidence interval). * shows a statistically significant increase 
of colocalization to ENmut-T (P < 0.01).
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adenosine deaminase, Gal4 and zinc finger motifs are
fused with the FokI DNA cleavage domain (FN). The
most extensively studied group of chimeric nucleases is
based on zinc finger nucleases (ZFNs), because zinc fin-
ger motifs can be designed to bind a large range of DNA
sites [28]. It was reported that ZFNs could cleave their
chromosomal targets in frog oocytes, Drosophila, plant
cells, Caenorhabditis elegans and human cells [29,30].
However, so far, there has been no report of telomere spe-
cific endonuclease being created. The cleavage domain of
type IIS REase has no specificity for any target sequence,
but the endonuclease domains found in several target-
specific LINEs are highly sequence-specific. Thus, the
coupling of such a LINE endonuclease with a DNA-bind-
ing protein will produce an endonuclease with improved
site-specificity.
To cut human (TTAGGG)n telomeric repeats specifi-
cally, we first tried to use TRAS1EN (EN), the endonu-
clease domain from the silkworm telomere-specific LINE
TRAS1, but it had insufficient activity and specificity.
Therefore, we tried to make chimeric endonucleases of
EN or FN fused with the human telomeric repeat binding
protein TRF1. Five chimeric EN endonucleases and two
chimeric FN endonucleases cut the telomeric repeats
(pTR80) specifically but did not cut the nontelomeric
sequence in the same enzyme concentration (pNTR; Fig-
ures 2, 3). There was no major difference in specificity for
pTR80 with various constructs (Figure 3) which sug-
gested that the domain constituents and structures of chi-
meric endonucleases do not affect their activities, and
that the TRF1 Myb domain included in all chimeric
enzymes is essential for cleavage specificity to human
telomeric repeats. FN-T and T-FN digested both strands
of (TTAGGG/CCCTAA)n repeats with different cleavage
sites on the top strand, but chimeric enzymes based on
TRAS1EN digested both strands specifically as does
TRAS1EN itself (Additional file 4), so the specificity of
Figure 6 Inhibition of cell proliferation by an expressed EN-T endonuclease. A series of U2OS and HFL-1 cells were planted in 12 well plates (3 
× 105 per well). We added recombinant adenovirus to 1 ml medium at low concentrations of 4.4 × 105 pfu/ml (a), (c) or 8.8 × 105 pfu/ml (b), (d). Cell 
growth curves for U2OS (a), (b) and HFL-1 (c), (d) are shown (bar: ± standard deviation, n = 4). Numbers of cells at 3 days after infection are indicated 
as 1.0. EN-T expressing HFL-1 cell cultures died by day 17.
Figure 7 Analysis of the inhibition of U2OS cancer cell growth. We added recombinant adenovirus at the concentration of 8.8 × 105 pfu/ml to the 
medium. (a) Numbers of U2OS cells after infection of each virus construct. Cell numbers at every 2 days starting from 1 day after infection are shown. 
Cell number at 1 day after infection is indicated as 1.0. (b) Telomere digestion by expressed chimeric endonucleases. We performed TRF assay with 
U2OS cells 3, 7 and 13 days after viral infection. (c) Immunoblot analysis of U2OS cell extracts harvested 3, 7 and 13 days after viral infections. p53 and 
p16 are markers of cellular senescence. Anti-HA antibody (HA) was used to detect chimeric endonucleases. α-tubulin and β-actin expression were 
used as loading controls. (d, e) We performed a senescence-associated (SA) β-galactosidase assay (see Methods) on day 13 cells. EN-T expressing cells 
show senescent phenotype, that is, an enlarged and flattened appearance and increased SA β-galactosidase activity as shown in (d) (two different 
fields are shown for each sample; the scale bar is 100 μm), and the percentage of the SA β-galactosidase positive cells is shown in (e) (bar: 95% confi-
dence interval).
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ric constructs. The EC50 for cutting telomeric repeat
DNA of FN-T, the most active enzyme in vitro, was 0.011
μM and the value of EN-T was 0.10 μM (Figure 3j). Both
values seem low enough to be functional in the cell, in
comparison with other active enzymes such as ZFN [18]
(EC50, ~0.01 μM) and artificial homing endonuclease
[14] (EC50, ~0.2 μM).
When these chimeric endonucleases were expressed in
cancer cells, T-EN and EN-T moved to telomeres (Figure
5a) where they induced double-strand breaks (Figure 5b,
c) and telomere digestion (Figure 4e). In contrast, T-FN
could not move into the nucleus (Figure 5a) and T-FN
and FN-T showed insufficient double-strand breaks at
telomere (Figure 5c). Thus, neither produced telomere
digestion in vivo (Figure 4a, c), although they have strong
activities in vitro. T-FN may lose its NLS function within
the TRF1 region because of conformational changes. In
addition, there are several reports of chromosomal dou-
ble strand breaks in vivo by FN chimeric endonuclease
[29,30] but the prokaryotic enzyme FN might have less
endonuclease activity for telomeres with a eukaryotic
chromatin structure than the telomere-specific endonu-
clease TRAS1EN.
Through telomere shortening, the cells expressing EN-
T, showed higher levels of cellular senescence markers
(Figure 7c-e) and suppressed cell proliferation (Figure 7a).
Thus, this chimeric endonuclease has the potential to be
used as anticancer reagents. During the progression of
cancer, one of the important mechanisms is telomerase
activation which circumvents the telomere-dependent
pathways of replicative senescence and crisis [4]. The lack
of telomerase expression in most normal somatic cells
makes this enzyme an attractive target when designing
anticancer therapeutics. Thus, the inhibition of telom-
erase by a dominant negative hTERT mutant in human
acute leukemia cells caused not only telomere shortening
but also induction of apoptosis [31]. However, it took
more than 40 days and such an approach would be valid
only in the telomerase positive cells. Here, we have suc-
ceeded in developing a novel approach to shorten telom-
eres directly and quickly by TRAS1EN chimeric
endonucleases. Compared with telomerase inhibitors,
which are not effective in telomerase-negative cancer
cells [30], these TRAS1EN chimeric enzymes have the
great advantage of being effective not only in the telom-
erase-positive cancer cells but also in telomerase-nega-
tive cancer cells such as U2OS. Future modifications of
the expression vectors using cancer-specific enhancer-
promoters, such as the hTERT promoter and the
hypoxia-inducible enhancer [32], to restrict the expres-
sion of the chimeric endonuclease in specific cancer cells
could reduce unwanted effects on normal cells. This
paper shows the concept of using such chimeric endonu-
clease to inhibit the growth of cancer cells by telomeric
repeat shortening.
Conclusions
We created novel chimeric endonucleases to cut human
telomeres by fusing the endonuclease domain of the silk-
worm's telomere specific non-LTR retrotransposon
TRAS1 to the human telomere-binding protein, TRF1.
These chimeric endonucleases were able to cut telomeric
repeats specifically and effectively not only in vitro but
also in human cell lines in vivo, and EN-T-expressing ade-
novirus suppressed the cell growth of cancer cells in a few
weeks. This report shows the possibility of cancer gene
therapy by rapid telomere shortening.
Methods
Cloning of TRF1, TRAS1EN and FN in the expression vector
Three-dimensional modelling of chimeric proteins was
performed with PyMol v0.99-rc6 http://www.pymol.org.
We started from the co-crystal structure of the Myb
domain of TRF1 and DNA (PDB ID: 1W0T), then over-
laid EN (PDB ID: 1WDU) or FN (PDB ID: 1FOK).
Although the co-crystal structure of EN and DNA has not
yet been clarified, the interaction between EN and DNA
was surmized via homology modelling using the crystal
structure of DNaseI (PDB ID: 1DNK) [11]. The TRF1,
TRF1 Myb domain, and TRF1 NLS-Myb domain were
amplified by polymerase chain reaction (PCR) with Pfu
Turbo DNA polymerase (Stratagene, CA, USA) using
primers TRF1-f-Nco-Nhe, TRF1M-f-Nco-Nhe,
TRF1NM-f-Nco-Nhe and TRF1-b-Sal-Not (Additional
file 6) from HEK293 cell cDNA. EN and EN(H258A) were
amplified using primers T1EN-f-Sal-Nhe and T1EN-b-
Nco-Not (Additional file 6) from plasmid pHisT1EN or
pHisT1EN(H258A) [9] and FN was amplified using prim-
ers FN-f-Sal-Nhe and FN-b-Nco-Not (Additional file 6)
from plasmid pML109RM119-1 (ATCC biological
resource centre). All primers were designed to contain
restriction endonuclease sites and PCR products were
digested with the corresponding enzymes (Figure 1). The
products were cloned into the pET21b expression vector
(Novagen), which is an expression vector for E. coli and
contains a His tag in the C-terminal end. To produce chi-
meric constructs, in the case of pET21b-EN-T vector,
TRF1 was subcloned into pET21b digested with NheI and
NotI, and then TRAS1EN was subcloned into pET21b-
TRF1 digested with NheI and NcoI. Other vectors were
constructed similarly. The insert sequence of a candidate
clone was confirmed. Adenovirus expression vectors
were constructed from pAxCAwtit (TAKARA), which
contains the CAG (chicken beta-actin promoter and
cytomegalovirus immediate-early enhancer) promoter.
Insert sequences were amplified from each pET21b vec-
tor using 5'-phosphorylated primers Kozak-HA-rbs and
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tit digested with SwaI. Recombinant adenoviruses were
generated according to the manufacturer's procedures.
Recombinant pAxCAwtit vectors were digested with
NspV and the linearized adenovirus DNAs were trans-
fected into human 293 cells. Recombinant adenoviruses
were generated in 293 cells. The map of adenovirus vec-
tor is shown in Additional file 7.
Expression and purification of chimeric endonucleases
The plasmids containing chimeric endonucleases were
transformed into the E. coli strain Rosetta2(DE3)/pLysS
(Novagen) plus pG-KJE8 (TAKARA). We used the
Rosetta2 E. coli strain because this strain carried a plas-
mid containing tRNA genes to decode rare E. coli codons,
and the strain was designed to enhance the expression of
eukaryotic proteins. The plasmid pG-KJE8, which con-
tains chaperons to facilitate protein folding and enhance
production of active proteins, was co-transformed.
Transformants were grown in 10 ml LB containing 50 μg/
ml ampicillin, 20 μg/ml chloramphenicol, 100 μg/ml
kanamycin, 5 ng/ml tetracycline, and 0.5 mg/ml L-arabi-
nose culture at 37°C until the optical density at 600 nm
(OD600) reached 0.6. Isopropyl-β-D-thiogalactopyrano-
side (IPTG) was then added to a final concentration of 1
mM, and incubation was continued for 12 h at 25°C. Pro-
tein purification was carried out according to the manu-
facturer's protocol for Ni-NTA agarose (Qiagen, CA,
USA). Glycerol up to a concentration of 5% was added to
the eluted proteins which were stored at -80°C. Eluates
were run on SDS-PAGE and the target proteins were
detected as bands of predicted molecular masses. We cal-
culated the percentage of the target protein in the total
eluted proteins from Additional file 2b by quantification
with ImageJ v. 1.34s (National Institutes of Health [NIH],
MD, USA). The concentrations of the total eluted pro-
teins were determined by Bradford assay using Proteo-
stain Kit (Dojindo, MD, USA).
Assays for endonucleolytic activities
The telomeric repeat plasmid pTR80 was constructed
from a PCR product of an extended primer dimer of
(TTAGGG)5 and (CCCTAA)5 primers. A non-telomeric
repeats (NTR) sequence was randomly selected from
human mRNA, and 2022-2672 bp of Tat-SF1 (GenBank
accession number U76992) was amplified with primers
dT18 and NTR-f (Additional file 6) and cloned into the
pGEM T-Easy vector (Promega, WI, USA). For quantita-
tive chimeric endonuclease activity assays, plasmid
pTR80 and pNTR were digested with the restriction
endonuclease ScaI to make a linear substrate with telo-
meric repeats positioned in the centre of the DNA strand.
Then, DNA was purified using the PCR clean-up kit
(Sigma, NY, USA). DNA concentration was determined
spectrophotometrically at 260 nm. Chimeric endonu-
clease was added to 10 μl of reaction buffer containing 1.6
ng/μl substrate DNA. Samples were incubated for 1 h at
25°C, and the reaction products were analysed by agarose
gel electrophoresis. Ethidium bromide-stained gels were
digitized with PrintGraph (Atto, Tokyo, Japan). The
intensity of the product bands was quantitated using
ImageJ v. 1.34s (NIH). Assays for oligonucleotide endonu-
cleolytic activities were performed as described previ-
ously [9]. Oligonucleotides were labelled at the 5' end by
the enzymatically catalyzed transfer of 32P from [γ-32P]
adenosine triphosphate (ATP) with T4 polynucleotide
kinase. The oligonucleotide concentration was fixed at
100 nM with adding nonlabelled oligonucleotides. The
reaction buffer for chimeric endonucleases contained 5
mM HEPES-KOH (pH 7.9), 10 mM NaCl, 2 mM MgCl2,
100 μg/ml BSA and 500 nM non-specific oligonucleotide,
NTR to suppress non-specific binding of misfolded chi-
meric endonuclease to non-telomeric sequence. This
mixture was treated with a purified chimeric endonu-
clease in 10 μl of reaction buffer for 1 h at 25°C. The reac-
tion mixture was denatured in a loading buffer containing
75% formamide for 5 min at 95°C, immediately chilled on
ice and run on a 28% Long Ranger polyacrylamide dena-
turing sequencing gel (Lonza, Basel, Switzerland). Quan-
titation of the reaction products was carried out with a
BAS 5000 imaging analyser system (Fujifilm).
Various-sized telomeric repeat oligonucleotides were
end-labelled with T4 polynucleotide kinase and [γ-32P]
ATP and were used as molecular size markers: dG8,
dG14, dG20, dG26, dC9, dC15, dC21 and dC27 (Addi-
tional file 6).
Electrophoretic mobility-shift assay
DNA probes were 5'-end-labelled as described earlier [9],
and were gel-purified. About 15 fmol of DNA was
labelled in a 10 μl reaction and the final probe concentra-
tion in binding assays was <10 nM. Binding reactions
were carried out by incubating the indicated amounts of
protein (see figure legends for details) in 10 μl of a reac-
tion mix of 20 mM Hepes (pH 7.9), 150 mM KCl, 0.1 mM
EDTA, 1 mM DTT, 4% Ficoll, 5% glycerol, 0.1 mg/ml of
BSA and 3 ng/μl salmon sperm DNA. Samples were incu-
bated at 4°C for 60 min and then run on native 5% poly-
acrylamide gels as described [33].
Cell cultures and adenovirus production
Two hundred and ninety-three U2OS, CCF-STTG1 and
HFL-1 cells were cultured in Dulbecco's modified Eagle's
medium with 10% fetal bovine serum [34]. All cell lines
were provided from the RIKEN BioResource Center (Iba-
raki, Japan). Cells were routinely passaged at 80% conflu-
ence. Adenoviruses were used as freeze-thaw lysates, and
their titres were estimated following the manufacturer's
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(TAKARA, WI, USA) for each virus (n = 16). Transfec-
tions were performed with FuGene HD (Roche) accord-
ing to the manufacturer's procedure. Four separate
microscope images were used for counting the number of
cells with CellProfiler [35].
Telomere length measurement
Genomic DNA was purified with PUREGENE (Gentra,
WA, USA) and digested with HinfI. Digests were sepa-
rated on a native 0.8% agarose gel, blotted in 0.4 M NaOH
onto a Hybond N+ membrane (Amersham, Uppsala,
Sweden) and hybridized with the RI-labelled (CCCTAA)5
and 1490-1467 bp of L1 (Additional file 6; GenBank
accession number X52235.1) probes in hybridization buf-
fer (6× saline-sodium citrate [SSC], 1% sodium dodecyl
sulphate [SDS], 5× Denhardt's solution, 2.5 μg/ml salmon
sperm DNA) at 37°C for 12 h. The membrane was
washed several times with wash buffer (4× SSC, 0.1%
SDS) for 10 min at 37°C. Quantitation of the reaction
products was carried out with a BAS 5000 imaging analy-
ser system (Fujifilm).
Immunoblotting analysis
Cells were trypsinized, washed once with PBS and subse-
quently lysed in 200 mM Tris-HCl pH 6.8, 4% SDS, 20%
glycerol, 200 μM DTT and 0.2% bromophenol blue.
Lysates were separated on SDS polyacrylamide gels (29:1
acrylamide: bisacrylamide, 8% gel) and transferred onto
BioTrace PVDF (Pall) for 70 min at 14 V. Membranes
were preincubated in TBST (0.1% Tween20 in 1× TBS)
containing 5% BSA for 30 min and then incubated with
primary antibodies in Can Get Signal Solution 1
(TOYOBO, Osaka, Japan) for 1 h, followed by three 10
min washes with TBST. The following antibodies were
used: TRF2, IMGENEX #IMG-124A; γ-H2AX, LPBIO
#AR-0149; HA, BETHYL #A190-108A; p53, EXBIO #11-
114-C100; p16INK4a, Thermo #MS-383-P0; α-Tubulin,
CEDARLANE #CLT9002 and β-Actin, Abcam #ab8226.
Membranes were incubated for 1 h with horseradish per-
oxidase conjugated anti-mouse or anti-rabbit antibodies
(Amersham) in Can Get Signal Solution 2 (TOYOBO)
and were developed using the ECL PLUS system (Amer-
sham). All samples were loaded in the same gel and the
blotted membrane was re-stained with different antibody
after stripping in 2% SDS, 100 mM β-mercaptoethanol
and 62.5 mM Tris-HCl pH 7 at 50°C for 30 min.
Immunofluorescence
The cellular localization of chimeric endonucleases was
visualized through indirect immunofluorescence. Cells
were grown on glass-bottomed dishes, washed once with
PBS, fixed with methanol, and permeabilized in a Triton
X-100 solution (0.5% Triton X-100 in phosphate-buffered
saline) four times for 10 min. The cells were subsequently
blocked for 1 h at 25°C in 10% sheep serum, stained with
primary or fluorescence-conjugated secondary antibod-
ies for 1 h at 37°C, and then visualized under an Olympus
IX51 fluorescence microscope. Anti-TRF2 antibody
(IMGENEX, CA, USA; #IMG-124A) was used to detect
telomere, because TRF2 is another telomere binding pro-
tein being independent of TRF1, and anti-HA antibody
(BETHYL, TX, USA; #A190-108A) was used to detect
chimeric endonucleases. Secondary antibodies were
Alexa Fluor 488 or 555-conjugated goat anti-mouse or
anti-rabbit antibodies (Molecular Probes, CA, USA).
Senescence-associated beta-galactosidase staining
Senescence-associated beta-galactosidase (SA β-gal)
activity at pH 6.0 is a commonly used cellular senescence
marker [36]. Positive cells were detected by the modified
method of Dimri et al. [36]. The monolayers of cells were
washed with PBS and then fixed with 1% glutaraldehyde
for 5 min. The cells were washed again twice with PBS,
then staining solution was added [1 mg/ml 5-bromo-4-
chloro-3-inolyl-b-D-galactoside (X-gal), 40 mM sodium
phosphate, pH 6.0, 5 mM potassium ferrocyanide, 5 mM
potassium ferricyanide, 150 mM NaCl, 2 mM MgCl2].
After the cells were further incubated at 37°C for 24 h, the
percentage of stained cells was counted. The number of
blue structures was counted in four fields (from a total of
average 3.76 × 103 cells).
Additional material
Additional file 1 Figure S1 - The amino acid sequences of protein link-
ers. The protein linker sequences of T-EN, M-EN, EN-T, EN-NM, EN-M, T-FN 
and FN-T are shown. The second structures of these proteins are predicted 
by SSpro http://scratch.proteomics.ics.uci.edu/. 67 -267 a.a. of the linker of 
EN-T and FN-T are TRF Homology domain (TRFH) which has tight structure, 
so we calculated linker length except this domain. Most of these linkers are 
nonstructural peptide.
Additional file 2 Figure S2 - SDS-PAGE of purified chimeric endonu-
cleases. (a) Selection of an appropriate E. coli strain for the effective expres-
sion of human protein (TRF1). Recombinant TRF1 protein was purified with 
a His tag. Protein extracts produced from bacterial cells were purified using 
Ni-NTA (nitrilotriacetic acid) agarose beads, and separated on a sodium 
dodecyl sulphate (SDS)-PAGE gel and stained with Coomassie brilliant blue. 
We confirmed that the molecular mass of overexpressed protein is identical 
to TRF1 (53.6 kDa). * indicates non-specific protein bound to Ni-NTA beads. 
The expression of human protein TRF1 increased with chaperon and rare 
tRNA. (b) SDS-PAGE of purified chimeric endonucleases using Rossetta2/
pLysSRARE2 (Kmr) strain in (a). The molecular weight of each purified pro-
tein was the same as the calculated weight. Arrows shows purified protein.
Additional file 3 Table S1. Cleavage activity of chimeric endonucleases.
Additional file 4 Figure S3 - Cleavage of telomeric repeats by chimeric 
endonucleases. (a, b) RI-labelled double-strand oligo DNA substrate, TR5 
containing 5 TTAGGG repeats was digested with chimeric endonuclease, 
and separated on polyacrylamide gels. The DNA concentration was 100 
nM, and protein concentration was about 0.3 μM except for EN (6 μM), and 
FN-T (0.02 μM). The (TTAGGG)5 strand of TR5 was labelled in (a) and the 
(CCCTAA)5 strand was labelled in (b). Black arrowheads show major cleav-
age bands which were cleaved in every telomeric repeat; gray arrowheads 
show minor cleavage bands. (c) Schematic cleavage sites are shown based 
on the results of (a) and (b).
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AP: apurine/apyrimidine; APT: adenosine triphosphate; EN: endonuclease-like
domain; FN: FokI cleavage domain; LINE: long interspersed nuclear element;
LTR: long terminal repeat; NLS: nuclear localization signal; NTR: non-telomeric
repeat; PBS: phosphate buffered saline; PCR: polymerase chain reaction; SA:
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